Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the market? This article walks through what the current numbers may be telling ...

Anthropic’s Cowork brings Claude Code–style AI agents to the desktop, letting Claude access and manage local files and browse ...

Digitally remastered episodes of the beloved period drama "Mad Men" debuted on HBO Max this week with a host of production errors that inexplicably made their way to the streaming platform. HBO Max ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

One administration official is leading a government-funded cultural institution in Washington as he conducts diplomatic talks with foreign countries. Another is in charge of two agencies, each with ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $5.03, demonstrating a -1.57% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.22%.

Abstract: Multiple parallel sparse linear arrays (MPSLAs) can be strategically deployed in two-dimensional (2D) or threedimensional (3D) space, offering a unique advantage by enabling easy conformal ...